396-02-1

Basic information

• Product Name: 2,4-DICHLORO-7-(TRIFLUOROMETHYL)QUINAZOLINE
• Synonyms: 2,4-DICHLORO-7-(TRIFLUOROMETHYL)QUINAZOLINE;2,4-Dichloro-7-(trifluoromethyl)
• CAS NO: 396-02-1
• Molecular Formula: C₉H₃Cl₂F₃N₂
• Molecular Weight: 267.037
• Mol File: 396-02-1.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 222.3 °C at 760 mmHg
• Flash Point: 88.3 °C
• Appearance: /
• Density: 1.595 g/cm³
• Vapor Pressure: 0.152mmHg at 25°C
• Refractive Index: 1.571
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -1.54±0.30(Predicted)
• CAS DataBase Reference: 2,4-DICHLORO-7-(TRIFLUOROMETHYL)QUINAZOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-DICHLORO-7-(TRIFLUOROMETHYL)QUINAZOLINE(396-02-1)
• EPA Substance Registry System: 2,4-DICHLORO-7-(TRIFLUOROMETHYL)QUINAZOLINE(396-02-1)

Safety Data

• Hazardous Substances Data: 396-02-1(Hazardous Substances Data)

Usage

General Description

2,4-Dichloro-7-(trifluoromethyl)quinazoline is a synthetic chemical compound with the molecular formula C9H4Cl2F3N3. It is a quinazoline derivative with two chlorine atoms and a trifluoromethyl group attached to the 7th carbon atom. 2,4-Dichloro-7-(trifluoromethyl)quinazoline is widely used in the pharmaceutical and agricultural industries for its potential as a building block for the synthesis of biologically active molecules and as a herbicide for controlling broadleaf weeds in various crops. Its molecular structure and properties make it a valuable tool for the development of new drugs and agrochemicals. However, proper handling and safety precautions are necessary due to its potential toxic effects.

InChI:InChI=1/C9H3Cl2F3N2/c10-7-5-2-1-4(9(12,13)14)3-6(5)15-8(11)16-7/h1-3H

Upstream product

• 10026-13-8 phosphorus pentachloride 
• 3833-78-1 7-(trifluoromethyl)quinazoline-2,4(1H,3H)-dione 
• 10025-87-3 trichlorophosphate 
• 89-77-0 2-Amino-4-chlorobenzoic acid 
• 402-13-1 2-amino-4-trifluoromethylbenzoic acid 
• 320-94-5 2-nitro-4-trifluoromethylbenzoic acid 
• 778-94-9 2-nitro-4-trifluoromethyl-benzonitrile 
• 3833-78-1 7-trifluoromethyl-quinazoline-2,4-diol 
• 57-13-6 urea 

Downstream Products

• 159870-93-6 2-chloro-7-(trifluoromethyl)quinazolin-4(3H)-one 
• 1379685-86-5 2-[(1R,2R)-2-(dimethylamino)cyclohexylamino]-7-(trifluoromethyl)quinazolin-4(3H)-one 
• 1379685-87-6 2-[(1R,2R)-2-(diethylamino)cyclohexylamino]-7-(trifluoromethyl)quinazolin-4(3H)-one 
• 1379685-88-7 2-[(1R,2R)-2-(dipropylamino)cyclohexylamino]-7-(trifluoromethyl)quinazolin-4(3H)-one 
• 1379685-89-8 2-[(1R,2R)-2-(piperidin-1-yl)cyclohexylamino]-7-(trifluoromethyl)quinazolin-4(3H)-one 
• 1379685-90-1 2-[(1R,2R)-2-(isopropylamino)cyclohexylamino]-7-(trifluoromethyl)quinazolin-4(3H)-one 
• 1379685-93-4 2-[(1S,2S)-2-(dimethylamino)-1,2-diphenylethylamino]-7-(trifluoromethyl)quinazolin-4(3H)-one 
• 1379685-94-5 2-[(1S,2S)-2-amino-1,2-diphenylethylamino]-7-(trifluoromethyl)quinazolin-4(3H)-one 
• 1379686-21-1 CHF₃O₃S*C₁₇H₁₄F₃N₃O 
• 1388043-95-5 2-chloro-7-(trifluoromethyl)quinazoline 

Relevant articles and documents

DIACYLGLYCEROL KINASE MODULATING COMPOUNDS

The present disclosure provides diacylglycerol kinase modulating compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV or hepatitis B virus infection. The compounds can be used alone or in combination with other agents.

METHODS OF CULTURING AND/OR EXPANDING STEM CELLS AND/OR LINEAGE COMMITTED PROGENITOR CELLS USING AMIDO COMPOUNDS

Provided are methods for expanding stem cells and/or lineage committed progenitor cells, such as hematopoietic stems cells and/or lineage committed progenitor cells, at least in part, by using compounds that antagonize AhR. The compounds are represented by formulae (I) (II) (III) (IV), wherein the letters and symbols a, b, c, d, e, f, g, Z, R1b, R2a and R2b have the meanings provided in the specification. Also provided are compositions comprising stem cells and/or lineage committed progenitor cells expanded by methods disclosed herein and methods for the treatment of diseases treatable by same.

BICYCLIC DERIVATIVE CONTAINING PYRIMIDINE RING, AND PREPARATION METHOD THEREFOR

The present invention provides: a bicyclic derivative comprising a pyrimidine ring, or a pharmaceutically acceptable salt thereof; a preparation method therefor, a pharmaceutical composition comprising the same; and a use therefor. According to the present invention, the bicyclic compound derivative comprising a pyrimidine ring, or a pharmaceutically acceptable salt thereof acts as a 5-HT4 receptor agonist, and thus can be usefully applied to the prevention or treatment of dysfunction in gastrointestinal motility, for example, gastrointestinal diseases such as gastroesophageal reflux disease (GERD), constipation, irritable bowel syndrome (IBS), dyspepsia, post-operative ileus, delayed gastric emptying, gastroparesis, intestinal pseudo-obstruction, drug-induced delayed transit, diabetic gastric atony and the like.